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ORIGINAL ARTICLE
The association between plasma miR-122-5p release pattern at admission and
all-cause mortality or shock after out-of-hospital cardiac arrest
Patrik Giljea#, Martin Frydlandb, John Bro-Jeppesenb, Josef Dankiewiczc, Hans Fribergc, Malin Rundgrenc,
Yvan Devauxd, Pascal Stammete, Mariam Al-Mashatf, Jonas J€ogif, Jesper Kjaergaardb, Christian Hassagerb and
David Erlingea
aDepartment of Cardiology, Clinical Sciences, Lund University, Lund, Sweden; bThe Heart Centre, Department of Cardiology, Copenhagen
University Hospital, Copenhagen, Denmark; cDepartment of Intensive and Perioperative Care, Clinical Sciences, Lund University, Lund,
Sweden; dCardiovascular Research Unit, Luxembourg Institute of Health, Luxembourg, Luxembourg; eThe Medical Department, National
Rescue Services, Luxembourg, Luxembourg; fDepartment of Clinical Physiology, Clinical Sciences, Lund University, Lund, Sweden
ABSTRACT
Background: Data suggests that the plasma levels of the liver-specific miR-122-5p might both be a
marker of cardiogenic shock and a prognostic marker of out-of-hospital cardiac arrest (OHCA). Our aim
was to characterize plasma miR-122-5p at admission after OHCA and to assess the association
between miR-122-5p and relevant clinical factors such all-cause mortality and shock at admission
after OHCA.
Methods: In the pilot trial, 10 survivors after OHCA were compared to 10 age- and sex-matched con-
trols. In the main trial, 167 unconscious survivors of OHCA from the Targeted Temperature
Management (TTM) trial were included.
Results: In the pilot trial, plasma miR-122-5p at admission after OHCA was 400-fold elevated com-
pared to controls. In the main trial, plasma miR-122-5p at admission was independently associated
with lactate and bystander cardiopulmonary resuscitation. miR-122-5p at admission was not associated
with shock at admission (p¼ 0.14) or all-cause mortality (p¼ 0.35). Target temperature (33 C vs 36 C)
was not associated with miR-122-5p levels at any time point.
Conclusions: After OHCA, miR-122-5p demonstrated a marked acute increase in plasma and was inde-
pendently associated with lactate and bystander resuscitation. However, miR-122-5p at admission was
not associated with all-cause mortality or shock at admission.
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Introduction
Sudden out-of-hospital cardiac arrest (OHCA) is a cause of
substantial mortality and morbidity (Dragancea et al. 2013).
After return of spontaneous circulation, the post cardiac
arrest syndrome ensues which is characterized by systemic
inflammation, ischemia/reperfusion injury and organ dysfunc-
tion (Nolan et al. 2008). Hypoxic hepatitis occurs in 3–18% of
OHCA-patients and is associated with increased intensive
care unit mortality (Champigneulle et al. 2016). In the clinic,
liver injury is usually detected by analyzing plasma levels of
alanine aminotransferase (ALT) and an ALT-elevation above
three times the upper limit of the normal range is a useful
indicator of liver damage with high sensitivity and specificity
(Senior 2012).
MicroRNAs (miRNAs) are short (18–23 nucleotides), non-
coding RNAs that have a central role in regulating transla-
tion and degradation of messenger RNAs (mRNAs) inside
the cell (Ha and Kim 2014). In addition, miRNAs are abun-
dant in the blood, where they are protected from
degradation by their association with proteins or extracellu-
lar vesicles (Arroyo et al. 2011). As some miRNAs also have a
high degree of tissue specificity and due to their stability
during storage and handling, miRNAs are potential diagnos-
tic and prognostic biomarkers (Fichtlscherer et al. 2011).miR-
122-5p is the most abundant miRNA in the human liver
(Jopling 2012, Ludwig et al. 2016). However, miR-122-5p is
largely absent in other organs including the brain and is
regarded as liver-specific (Jopling 2012). miR-122-5p is vital
for the regulation of lipid metabolism and cellular prolifer-
ation and has been associated with hepatitis and the devel-
opment of hepatocellular carcinoma (Hsu et al. 2012). In
plasma, miR-122-5p is a well-documented marker of both
acute and chronic liver injury. In response to injury, blood
levels of miR-122-5p seem to increase before aminotransfer-
ases, the most common clinical marker of active liver necro-
sis (Ward et al. 2014).
Recently, low levels of plasma miR-122-5p at 48 h after
OHCA was shown to be an independent predictor of poor
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neurological outcome and all-cause mortality after OHCA.
This was notable since previous studies have found high
plasma levels of miR-122-5p during cardiogenic shock in
patients and in pigs (Andersson et al. 2012, Cortez-Dias et al.
2016). Moreover, plasma levels of miR-122-5p during resusci-
tation for OHCA were higher among patients who died com-
pared to survivors (Wander et al. 2016). Plasma levels of miR-
122-5p after OHCA seem to fall between 24 h and 72 h after
OHCA but the timeframe between resuscitation and 24 h
after OHCA has not been evaluated (Devaux et al. 2017).
The aim of this study was to characterize plasma miR-122-
5p after OHCA. With regards to the available evidence, we
hypothesized that miR-122-5p would be elevated in survivors
from OHCA at admission compared to matched controls.
Furthermore, we aimed at assessing the association between
miR-122-5p at admission and relevant clinical factors such
as ALT, lactate, bystander CPR, targeted temperature man-
agement, hemodynamic/echocardiographic parameters and
shock at admission.
Clinical significance
 Plasma miR-122-5p at 48 h after OHCA is an independent
predictor of neurological outcome and all-cause mortality.
 Plasma miR-122-5p is elevated during cardiogenic shock
in patients and in pigs.
 In the present study, plasma miR-122-5p at admission
after OHCA was not associated with all-cause mortality,
target temperature or shock at admission.
Methods
Pilot trial
In the pilot trial, 10 randomly selected patients from a separ-
ate OHCA cohort were included (Gilje et al. 2014). These
were compared to a sex- and age-matched control group
consisting of 10 outpatients undergoing myocardial perfu-
sion scans due to suspicion of angina pectoris (5 women and
5 men in each group, median age 72 years in the control
group and 73 years in the patient group; p¼ not significant).
The patients in the pilot trial were not included in the main
trial and a comparison between the patients included in the
two trials can be found in Table 1. For details about the
miRNA-extraction in the pilot trial, see Supplementary file 1.
Main trial
Patients
The patients in the main trial originate from unconscious
patients admitted after OHCA of presumed cardiac cause
and were originally the Danish patients included in the
Targeted Temperature Management (TTM) trial (Nielsen et al.
2013). Details about inclusion criterions can be found in
Supplementary file 1.
Samples and clinical variables
Blood samples were obtained at admission followed by sam-
ples at 24, 48 and 72 h after return of spontaneous circula-
tion (ROSC). In the univariate models, lactate at admission,
LVIDD at admission, age, MAP, Creatinine admission, Time to
ROSC, HR at admission, central venous pressure (CVP) at
admission, first rhythm, target temperature, shock at admis-
sion, sex, bystander CPR, cardiac output at admission, LVEF
at admission, initial temperature and high-sensitivity
Troponin T at 48 h after OHCA were included. Missing values
were replaced by multiple imputation. In the multiple linear
regression and the logistic regression models, the variables
that were deemed to be the most clinically and scientifically
relevant were included. No patients were lost to follow up.
Biomarker analysis
Only miR-122-5p was analyzed in the current project and we
did not perform any multiple testing of other miRNAs.
RNA-extraction, cDNA-synthesis and quantitative PCR were
performed by Exiqon Services, Denmark. Normalization was
performed by using the average of the miRNAs that were
detected in all samples and most stably expressed. For this
purpose, hsa-miR23a-3p and hsa-miR-103a-3p were selected
by the Normfinder software (Aarhus, Denmark). For details
about the miRNA-extraction, see Supplementary file 1. ALT
was analyzed according to the routine methods at the
Copenhagen University Hospital and expressed as inter-
national units IU/litre.
Table 1. Patient characteristics.
Pilot trial (n¼ 10) Main trial (n¼ 167) p-value
Age (years) 73 62 <0.05
Sex (female) 5/10 (50%) 21/167 (13%) <0.01
Out-of-hospital CA 9/10 (90%) 167/167 (100%) 0.06
Bystander CPR (Yes) 6/10 (60%) 133/167 (80%) 0.23
Time CA to ROSC (min) 20 (12;28) 23 (14;30) 0.49
First rhythm (VT/VF) 8/10 (80%) 146/167 (87%) 0.61
Alive 180 days after CA (yes) 7/10 (70%) 109/167 (65%) 1.00
Shock at admission (yes) – 17/167 (10%) –
MAP at admission (mm Hg) – 71 (65;80) –
Creatinine at admission (mg/dl) – 97 (82;116) –
Lactate at admission (mmol/l) – 7.5 (3.7;11.0) –
Heart rate at admission (bpm) – 72 (61;85) –
LVIDD at admission (cm) – 5.4 (5.9;4.8) –
CA: cardiac arrest; CPR: cardiopulmonary resuscitation; ROSC: return of spontaneous circulation; VT:
ventricular tachycardia; VF: ventricular fibrillation; MAP: mean arterial pressure; LVIDD: left ventricular
internal diameter end diastole.
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Mortality and shock
All-cause mortality was assessed at 180 days after cardiac
arrest. Cause of death was assessed by the treating physician.
A subgroup was pre-specified based on the presence of
shock at admission. Shock at admission was defined as a sys-
tolic blood pressure of <90mmHg for >30min or the need
of supportive measures to maintain a blood pressure
90mmHg and/or clinical signs of end-organ hypoperfusion
(cool extremities, urine output of <30ml/h).
Ethics approval and consent to participate
The samples in the pilot trial were analyzed in concordance
with the approval of Regional Ethical Review Board at Lund
University (411/2004 and 223/2008). Informed consent was
sought from the patient’s kin or retrospectively from
the patient.
The samples in the main trial were collected as a part of
the TTM trial (Nielsen et al. 2013). This protocol was
approved by the ethics committee of Copenhagen
University. Eligible patients were unconscious and unable to
give informed consent in the acute setting. Randomization
was justified before informed consent could be obtained
according to the declaration of Helsinki Section 2.5. Patients
regaining consciousness were asked for informed consent.
Statistics
Pilot trial
The Wilcoxon matched-pairs signed rank test was used for
comparisons between paired groups. Comparisons between
non-paired groups were performed using the
Mann–Whitney test.
Main trial
Data are presented as medians, interquartile range, counts
and proportions (%). Due to skewed distributions, miR-122-
5p was log2-transformed prior to analysis. Missing data was
handled with 10-fold multiple imputation (MCMC procedure).
Continuous variables with normal distribution were com-
pared using ANOVA. In order to compare pooled data from
multiple imputation datasets, non-parametric continuous
data were log-transformed before ANOVA analysis.
Differences between repeated measurements of parametric
groups were assessed using repeated measures of ANOVA
with the Sidak correction. Pearson’s chi Square test and
Fisher’s test was used for categorical data. Correlations
between continuous data were assessed using Pearsons and
Spearman correlation coefficients for parametric and non-
parametric data, respectively. Associations between miR-122-
5p and other parameters were investigated by multiple linear
regression and logistic regression analysis. As the propor-
tional hazard assumption was not fulfilled, logistic regression
rather than Cox regression was performed. miR-122-5p at
admission was log2-transformed before being entered as an
independent variable in the logistic regression model. A p-
value <0.05 was considered significant. IBM SPSS Statistics
22 (Foster City, USA) and GraphPad Prism 6 (La Jolla, USA)
were used for the analyses.
Results
Pilot trial
In the pilot trial, 10 survivors of OHCA were included and
compared to 10 sex- and age-matched controls. At admis-
sion, the median plasma level of miR-122-5p was 404-fold
elevated in OHCA-patients compared to controls (p< 0.001).
At 48 h after OHCA there was no significant difference
between patients and controls (Figure 1).
Main trial
In total, 171 patients were eligible for analysis. Two patients
were excluded since blood samples were not available. Two
patients were considered as outliers due to miR-122-5p levels
deviating more than four standard deviations, and were
excluded. Hence, 167 patients were included. Patient charac-
teristics and a comparison to the pilot trial cohort can be
found in Table 1. A patient flow diagram of the main trial is
presented in Figure 2. One hundred and nine patients (65%)
were alive at 180 days after OHCA.
The cohort in the main trial was younger and had more
males compared to the pilot trial cohort. miR-122-5p was
available for 161 patients (96%) at admission, 151 patients
(90%) at 24 h, 145 patients (87%) at 48 h and 140 patients
(84%) at 72 h. With regard to sex, OHCA, bystander CPR, first
rhythm, alive at 180 days, shock at admission, time to ROSC,
target temperature and age, no data was missing. For the
other variables, the missing data were as follows: MAP at
admission: 10%; creatinine at admission: 2%; lactate at
admission: 17%; LVIDD at admission: 15%; CO at admission:
21%; CVP at admission: 21%; LVEF at admission: 21%;
Figure 1. At admission, patients in the pilot trial had a 404-fold elevation of
the median plasma level of miR-122-5p compared to controls (p< 0.001).
(The lines represents medians and the 95% CI, ¼p 0.01, ¼p 0.001,
ns¼ not significant).
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hs-Troponin-T: 8%; initial temperature: 2%; and HR at admis-
sion: 4%.
Kinetics of circulating miR-122-5p following OHCA
As in the pilot trial, miR-122-5p peaked at admission and
then declined before reaching a plateau level at 48 h
(Figure 3(a)). The median/mean plasma level of miR-122-5p
was 57-fold/140-fold elevated at admission compared to 72 h
after OHCA (p< 0.001).
Linear regression analyses
In the univariate regression analyses, miR-122-5p at admis-
sion was significantly correlated to lactate at admission
(b¼ 0.14, p< 0.01), time to ROSC (b¼ 0.03, p< 0.01) and
heart rate at admission (b¼ 0.02, p< 0.001). There were
inverse relationships between miR-122-5p at admission and
age (b¼–0.04, p< 0.05), mean arterial pressure (MAP) at
admission (b¼–0.02, p< 0.001), bystander CPR (b¼–1.29,
p< 0.01) and left ventricular internal diameter end diastole
(LVIDD) at admission (b¼–0.66, p< 0.05). Other variables
such as sex, creatinine, cardiac output at admission, central
venous pressure at admission, left ventricular ejection frac-
tion (LVEF) at admission, initial temperature and high-sensi-
tivity Troponin-T were not related to miR-122-5p in the
univariate analyses.
In the multiple linear regression analysis (r2¼0.23,
p< 0.001), lactate at admission, bystander CPR and LVIDD at
admission remained significantly associated with miR-122-5p
at admission (Table 2).
Figure 2. The study flow in the main trial.
Figure 3. (a, b) In the main trial, the plasma miR-122-5p at admission was 57 fold/140-fold (median/mean) elevated compared to the 72 h time point (p< 0.001).
(c, d) In the main trial, target temperature did not influence plasma levels of miR-122-5p or ALT. (Box and whisker plots are represented in the figures. The error
bars represent the 95% CI, ¼p 0.01, ¼p 0.001, ns¼ not significant).
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miR-122-5p according to targeted temperature
Target temperature (33 C vs 36 C) was not associated with
miR-122-5p at any time point (Figure 3(c)) and there were no
interactions between target temperature and miR-122-5p.
miR-122-5p and shock at admission
Information about shock at admission was available for 167
patients (100%). Seventeen patients (10%) had shock at
admission whereas 150 (90%) did not. There was a similar
release pattern of miR-122-5p regardless of whether or not
shock was present at admission. The median/mean plasma
level of miR-122-5p at admission among patients with shock
at admission was 1.8-fold/2.1-fold elevated compared to
patients without shock, but this was not statistically signifi-
cant (p¼ 0.14). In a logistic regression model including lac-
tate at admission and time to ROSC, miR-122-5p at
admission was not associated with shock at admission (OR:
1.04, 95% CI: 0.83–1.30, p¼ 0.76).
miR-122-5p and all-cause mortality
At 180 days after OHCA, 58 patients (35%) had died. With
regard to survival status at 180 days, neither the release pat-
tern of miR-122-5p nor the miR-122-5p levels at any time
point differed between the groups. In a logistic regression
analysis, miR-122-5p at admission was not associated with
all-cause mortality (p¼ 0.35) (Table 3).
Levels of miR-122-5p at admission could not discriminate
between cerebral (67% of deaths, n¼ 39) and cardiovascular/
multi-organ failure (29% of deaths, n¼ 17), causes of
death (p¼ns).
miR-122-5p and liver enzymes
The release pattern of ALT is shown in Figure 3(b). ALT did
not differ between the outcome groups (131 IU/l vs 144 IU/l
for survivors vs non survivors, respectively, p¼ns) or between
different causes of death (140 IU/l vs 144 IU/l for cerebral vs
cardiovascular/multi-organ failure, p¼ns). miR-122-5p at
admission was significantly correlated with ALT at all time-
points (at admission r¼ 0.59 (p< 0.001), at 24 h r¼ 0.59
(p< 0.001), at 48 h r¼ 0.57 (p< 0.001) and at 72 h r¼ 0.55
(p< 0.001)). miR-122-5p (log2) at admission was linearly
related to ALT (b¼ 0.32, p< 0.001) in the univariate analysis
(Figure 4). In the multivariable regression analysis (r2¼ 0.44,
p< 0.001) including, creatinine at admission, lactate at
admission, bystander CPR, shock at admission, age and sex,
miR-122-5p at admission remained independently associated
with ALT at admission (b¼ 0.29, 95% CI: 0.21–0.37,
p< 0.001). There were no significant associations between
ALT at admission and invasive hemodynamic parameters or
between ALT at admission and temperature assignment
(33 C vs 36 C) at any time point (Figure 3(d)).
Discussion
Treatment of patients that remain unconscious after OHCA is
challenging and biomarkers for early detection of organ dys-
function are needed. In this study of unconscious patients
with OHCA surviving to temperature management, the liver-
specific miR-122-5p had a very rapid release pattern and was
already 400-fold higher than levels in controls at admission.
After reaching the peak of admission, miR-122-5p levels
decreased rapidly before plateauing at 48 h. miR-122-5p at
admission correlated to lactate, bystander CPR and LVIDD,
Table 3. Logistic regression analysis with clinical variables to predict all-cause
mortality at 180 days after OHCA.
OR 95% CI p-value
Age (years) 1.08 1.04, 1.13 <0.001
Time CA to ROSC (min) 1.06 1.02, 1.09 <0.01
First rhythm (VT/VF) 0.18 0.05, 0.64 <0.01
miR-122 at admission (log2) 1.12 0.89, 1.40 0.35
Target temperature (33 C) 0.74 0.33, 1.70 0.48
Lactate at admission (mmol/l) 1.02 0.93, 1.11 0.69
Bystander CPR (yes) 1.08 0.40, 2.94 0.88
miR-122 at admission was not an independent predictor of all-cause mortality.
CI: confidence interval; CA: cardiac arrest; ROSC: return of spontaneous circula-
tion; VT: ventricular tachycardia; VF: ventricular fibrillation; CPR: cardiopulmon-
ary resuscitation.
Figure 4. At admission, miR-122 was linearly related to ALT. In the linear mul-
tiple regression model, miR-122 at admission was an independent predictor of
ALT at admission (b¼ 0.29, 95% CI: 0.21–0.37, p< 0.001).
Table 2. Multiple linear regression analysis for prediction of plasma miR-122
at admission.
b 95% CI p-value
Lactate at admission (mmol/l) 0.130 0.03, 0.23 <0.01
LVIDD (cm) –0.757 –1.25, –0.26 <0.01
Bystander CPR (yes) –1.092 0.16, 2.04 <0.05
Age (years) –0.031 –0.06, 0.00 0.06
MAP at admission (mm Hg) –0.022 –0.05, 0.01 0.09
Creatinine at admission (mg/dl) –0.004 –0.01, 0.00 0.11
Sex (male) 0.755 –0.36, 1.87 0.18
Time CA to ROSC (min) 0.006 –0.02, 0.03 0.65
Heart rate at admission (bpm) –0.006 –0.03, 0.02 0.58
Shock at admission (yes) 0.064 –1.23, 1.36 0.92
Lactate at admission, bystander CPR and LVIDD at admission were independ-
ent predictors.
CI: confidence interval; MAP: mean arterial pressure; LVIDD: left ventricular
internal diameter end diastole; CA: cardiac arrest; ROSC: return of spontaneous
circulation; CPR: cardiopulmonary resuscitation.
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but was not associated with all-cause mortality at 180 days
or shock at admission.
The acutely increased levels of plasma miR-122-5p at
admission harmonize with findings by Wander et al. (2016),
who reported an elevated plasma miR-122 already during
resuscitation from ventricular fibrillation compared to con-
trols. Plasma miR-122 during resuscitation was also higher
among patients surviving to discharge compared to those
who died in the field. However, resuscitation times were not
available which might confound the survival analysis. In con-
trast, Devaux et al. (2017) described an independent associ-
ation between lower levels of miR-122-5p at 48 h after OHCA
and a poor outcome. One might speculate that lower levels
of miR-122-5p at 48 h among patients with poor prognosis
represent a rebound phenomenon after high initial plasma
levels. However, miR-122-5p at admission was not associated
with all-cause mortality in our study.
In the multiple linear regression model, lactate at admis-
sion was independently associated with miR-122-5p at
admission. This association might reflect a reduced capability
of the liver to metabolise lactate through the Cori cycle
(Jansen et al. 2009). However, lactate is a surrogate marker
of hypoperfusion and closely relates to multiple organ dys-
function and shock (Jansen et al. 2009). Our results are in
line with previous findings in a pig cardiogenic shock model,
where miR-122-5p increased rapidly after induction of shock
and was correlated to pH and MAP during chock (Andersson
et al. 2012). We did not observe an association between MAP
and miR-122-5p at admission but MAP is an inadequate
marker of circulatory failure due to the common use of vaso-
pressors in the post cardiac arrest setting. Due to the acute
increase of miR-122-5p during the first hours after OHCA and
its association with lactate at admission, one could speculate
that miR-122-5p might be a hyper-acute marker of circula-
tory collapse and a very early marker of liver dysfunction. On
the other hand, patients with shock at admission in the pre-
sent study had only a non-significant increase of miR-122-5p
compared to patients without shock (p¼ 0.14) and the logis-
tic regression model could not detect any association
between miR-122-5p at admission and shock at admission.
However, since only 17 patients (10%) had shock at admis-
sion this might be a type II error and larger studies are
needed to further investigate miR-122-5p as a marker
of shock.
The association between miR-122-5p and bystander CPR
indicates that some of the release of miR-122-5p might be
secondary to traumatic injury. Moreover, bystander CPR is
often performed by laymen which might increase the risk of
inadvertent compression of the liver (Bossaert and Van
Hoeyweghen 1989). The inverse association between miR-
122-5p and LVIDD is not intuitive. Increased LVIDD is associ-
ated with cardiac preload, cardiac remodelling and reduced
LVEF in systolic heart failure (Wong et al. 2004). Previous
known heart failure was uncommon in the cohort (4%) and
there was no differences in LVIDD between the outcome
groups. The negative association between miR-122-5p and
LVIDD therefore remains unclear.
Our study has some strengths. First, the study includes a
relative large population and no patients were lost to follow
up. Second, all-cause mortality was used as endpoint. Third,
in the pilot study plasma miR-122-5 levels among patients
were compared to matched controls.
Limitations to the study includes that only one miRNA,
miR-122-5p, was evaluated. However, miR-122-5p was chosen
based on a literature review. The study was also underpow-
ered to assess the correlation between plasma levels of miR-
122-5p and subgroups, such as shock status at admission
and causes of death.
Conclusions
The liver-specific miR-122-5p in plasma seems to be a hyper-
acute biomarker after cardiac arrest and is 400-fold elevated
at admission after OHCA compared to controls. miR-122-5p
at admission is not associated with all-cause mortality or
presence of shock at admission . A targeted temperature of
33 C compared to 36 C did not affect miR-122-5p levels.
miR-122-5p at admission was independently associated with
elevated lactate levels, LVIDD and bystander CPR.
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